Theoretical study of the influence of the circadian rhythm of plasma protein binding on cisplatin area under the curve
- 1 February 1986
- journal article
- conference paper
- Published by Springer Nature in Journal of Pharmacokinetics and Biopharmaceutics
- Vol. 14 (1) , 79-93
- https://doi.org/10.1007/bf01059285
Abstract
A mathematical model for area under the curve (AUC)determination is proposed taking into account the circadian variation of cisplatin protein binding. The main theoretical result obtained with the model is that early morning drug administration (2–4 AM) promotes the highest AUC.The model predicts a maximum AUCvariation, due to the binding variation, ranging between 2.4 and 15%. The minimum of AUCbetween 2.45 and 3.30 PM is in agreement with the minimum nephrotoxicity observed when cisplatin is injected in the afternoon.The model can be applied to other drugs that are irreversively bound to proteins or irreversively bound to other plasma components if the binding rate depends on the time of day. The variation intensity of AUC wasdemonstrated to depend on drug characteristics, but can never be higher than the circadian variation of the protein binding rate.This publication has 15 references indexed in Scilit:
- Circadian time dependence of cisplatin urinary kineticsClinical Pharmacology & Therapeutics, 1982
- Lethal nephrotoxicity and hematologic toxicity of cis-diamminedichloroplatinum ameliorated by optimal circadian timing and hydrationEuropean Journal of Cancer and Clinical Oncology, 1982
- CIRCADIAN STAGE DEPENDENCE OF CIS-DIAMMINEDICHLOROPLATINUM LETHAL TOXICITY IN RATS1982
- CISPLATIN URINARY PHARMACOKINETICS AND NEPHROTOXICITY - A COMMON CIRCADIAN MECHANISM1982
- Clinical kinetics of intact cisplatin and some related speciesClinical Pharmacology & Therapeutics, 1981
- Effects of “Jet Lag” on Hormonal Patterns. I. Procedures, Variations in Total Plasma Proteins, and Disruption of Adrenocorticotropin-Cortisol Periodicity*Journal of Clinical Endocrinology & Metabolism, 1981
- CISPLATIN - IMPACT OF A NEW ANTI-CANCER AGENT ON CURRENT THERAPEUTIC STRATEGIES1981
- Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusionCancer Chemotherapy and Pharmacology, 1980
- Plasma Protein Binding and Therapeutic Drug MonitoringTherapeutic Drug Monitoring, 1979
- Variation, diurnal and over longer periods of time, in blood haemoglobin, haematocrit, plasma protein, erythrocyte sedimentation rate, and blood chlorideEpidemiology and Infection, 1947